• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Ischemic stroke in the setting of supratherapeutic International Normalized Ratio following coronavirus disease 2019 infection: a case report
ConclusionsThis case report highlights the potential for thromboembolic events, including stroke, in patients with COVID-19 infection, even when receiving therapeutic anticoagulation therapy. Healthcare providers should be vigilant for signs of thrombosis in COVID-19 patients, particularly those with pre-existing risk factors. Further research is necessary to understand the pathophysiology and optimal management of thrombotic complications in COVID-19 patients.
Source: Journal of Medical Case Reports - May 31, 2023 Category: General Medicine Source Type: research

Proportion of Patients on Warfarin Therapy Who Are Eligible for Conversion to a Direct Oral Anticoagulant in the Setting of COVID-19
CONCLUSION AND RELEVANCE: Approximately 52% of patients on warfarin were eligible for DOACs. This presents an opportunity to reduce patient exposure to health care settings and health care utilization in the setting of COVID-19. Increased costs of DOACs need to be assessed.PMID:36373362 | PMC:PMC9663271 | DOI:10.1177/10600280221136874
Source: The Annals of Pharmacotherapy - November 14, 2022 Category: Drugs & Pharmacology Authors: Rachel Hess Elizabeth Renner Erin Mouland Denise Sutter-Long Nghi Ha Source Type: research

Evaluation of antithrombotic use and COVID-19 outcomes in a nationwide atrial fibrillation cohort
Conclusions Pre-existing AT use may be associated with lower odds of COVID-19 death and, while not evidence of causality, provides further incentive to improve AT coverage for eligible individuals with AF.
Source: Heart - May 25, 2022 Category: Cardiology Authors: Handy, A., Banerjee, A., Wood, A. M., Dale, C., Sudlow, C. L. M., Tomlinson, C., Bean, D., Thygesen, J. H., Mizani, M. A., Katsoulis, M., Takhar, R., Hollings, S., Denaxas, S., Walker, V., Dobson, R., Sofat, R., on behalf of the CVD-COVID-UK Consortium Tags: Open access, COVID-19 Cardiac risk factors and prevention Source Type: research

Impact of the COVID-19 pandemic on England's national prescriptions of oral vitamin K antagonist (VKA) and direct-acting oral anticoagulants (DOACs): An interrupted time series analysis (January 2019 - February 2021)
Conclusion: The overall oral anticoagulants use in this period was lower than expected, indicating a medical needs gap, possibly due to adherence issues. The potential clinical and logistical consequences warrant further study to identify contributing factors and mitigate avoidable risks.PMID:35582854 | DOI:10.1080/03007995.2022.2078100
Source: Current Medical Research and Opinion - May 18, 2022 Category: Research Authors: Sajidah Alkhameys Ravina Barrett Source Type: research

FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) events in p...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Warfarin anticoagulation in the Covid-19 pandemic: Telephone-based management at a regional hematology outpatient center in Joinville, Brazil
Oral anticoagulation (OA) is a well-established therapeutic approach for prevention of cardioembolic stroke and venous thromboembolism [1]. Adequate OA is a key element in reducing the high social burden, morbidity and mortality associated with cardiovascular diseases [2 –4]. In January 2020, the World Health Organization (WHO) declared COVID-19 a public health emergency of international concern. Since then, the strategy of social distancing has been adopted in most countries, with varying degrees of restriction and compliance.
Source: Thrombosis Research - July 9, 2021 Category: Hematology Authors: Kendra Lys Calixto Machado, Suzana Tanquella da Rosa, Soraya Dobner, Ivan Schneider Boettcher, Gilberto Comaru Pasqualotto, Adelina Elisabeth Lehmkuhl Lopes, Tain á de Araújo, Lysandra Patricia Luchtenberg Bolduan, Maria Daniela Holthausen Perico Colomb Tags: Letter to the Editors-in-Chief Source Type: research

Splenic Infarction with Aortic Thrombosis in COVID-19
Am J Med Sci. 2021 Jun 20:S0002-9629(21)00238-X. doi: 10.1016/j.amjms.2021.06.007. Online ahead of print.ABSTRACTCoronavirus disease 2019 (COVID-19) has been associated with an increased risk of venous and arterial thrombotic disease. Although pulmonary embolism has been the most common thrombotic complication, there have been recent reports of COVID-19-associated large-vessel ischemic stroke, acute upper- and lower-limb ischemia, as well as infarctions of the abdominal viscera, including renal, splenic, and small bowel infarctions. Here, we describe a case of splenic infarction (SI) associated with aortic thrombosis, whic...
Source: The American Journal of the Medical Sciences - June 23, 2021 Category: General Medicine Authors: Jaques Sztajnbok Lucas Mendes Cunha de Resende Brasil Luis Arancibia Romero Ana Freitas Ribeiro Jose Ernesto Vidal Claudia Figueiredo-Melo Ceila Maria Sant'Ana Malaque Source Type: research

Stroke Care during the COVID-19 Pandemic: International Expert Panel Review
This study, prepared by a large international panel of stroke experts, assesses the rapidly growing research and personal experience with COVID-19 stroke and offers recommendations for stroke management in this challenging new setting: modifications needed for prehospital emergency rescue and hyperacute care; inpatient intensive or stroke units; posthospitalization rehabilitation; follow-up including at-risk family and community; and multispecialty departmental developments in the allied professions.Summary: The severe acute respiratory syndrome coronavirus 2 uses spike proteins binding to tissue angiotensin-converting enz...
Source: Cerebrovascular Diseases - March 23, 2021 Category: Neurology Source Type: research